HippoT&C Establishes U.S. Subsidiary... "Targeting Global Market with DTx Technology"

BlueKare Designated as Innovative Medical Device
Establishing a Foothold for Entry into North America

HippoT&C, a company specializing in digital therapeutics (DTx), has established a local subsidiary in the United States, marking the start of its full-scale entry into the global market.

HippoT&C recently completed the establishment of 'HippoT&C USA, LLC' in Maryland and officially began operations, the company announced on the 21st.

The company’s flagship product, BlueKare, which is also Korea’s first digital therapeutic for depression, was designated as an innovative medical device by the Ministry of Food and Drug Safety on January 16. In addition, the company is preparing for prescriptions at tertiary hospitals by applying for a new health technology assessment deferral, thereby achieving successful technological validation and clinical results. Building on this momentum, HippoT&C plans to raise the profile of 'K-Digital Therapeutics' in the United States, the world’s largest healthcare market.

The U.S. subsidiary will play key roles, including: collaborating with the Inter-American Development Bank (IDB) on a pilot mental health service project for the Ministry of Education in El Salvador; pursuing U.S. Food and Drug Administration (FDA) 510(k) clearance for AttnKare, a digital therapeutic for attention deficit hyperactivity disorder (ADHD); evaluating cognitive abilities and securing real-world evidence (RWE) for low-income children in the U.S.; and attracting local investment.

Jung Taemyung, CEO of HippoT&C, stated, “The solid technological foundation we have built domestically is expected to be a strong driving force for obtaining approvals from overseas regulatory agencies and for carrying out pilot projects.” He added, “Based on our successful domestic model, we aim to achieve tangible results in the global market and expand our mission of enhancing mental health for humanity worldwide.”

Founded in 2020 by faculty members of Sungkyunkwan University, HippoT&C has been recognized for its technological capabilities, winning the CES 2022 Innovation Award and the 2025 Korea Artificial Intelligence Innovation Grand Prize in the AI Healthcare category. The company is currently preparing for the commercialization of BlueKare and is supplying its VR-based cognitive assessment solution, KagmoTest, to public institutions.